Delayed Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Score Improves Disparity in Access to Liver Transplant in the United States

被引:94
|
作者
Heimbach, Julie K. [1 ]
Hirose, Ryutaro [2 ]
Stock, Peter G. [2 ,3 ]
Schladt, David P. [3 ]
Xiong, Hui [3 ]
Liu, Jiannong [3 ]
Olthoff, Kim M. [4 ]
Harper, Ann [5 ]
Snyder, Jon J. [3 ,6 ]
Israni, Ajay K. [3 ,6 ,7 ]
Kasiske, Bertram L. [3 ,7 ]
Kim, W. Ray [3 ,8 ]
机构
[1] Mayo Clin, Dept Surg, Rochester, MN USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA
[3] Minneapolis Med Res Fdn Inc, Sci Registry Transplant Recipients, Minneapolis, MN USA
[4] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA
[5] United Network Organ Sharing, Richmond, VA USA
[6] Univ Minnesota, Dept Epidemiol & Community Hlth, Minneapolis, MN USA
[7] Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA
[8] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; SURVIVAL; OUTCOMES; IMPACT;
D O I
10.1002/hep.27704
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End-Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non-HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3-month delay before granting a MELD exception score of 25, (2) a 6-month delay before granting a score of 28, and (3) a 9-month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n=28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person-years for the current policy and for 3-, 6-, and 9-month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non-HCC candidates. Conclusion: A delay of 6-9 months would eliminate the geographic variability in the discrepancy between HCC and non-HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates. (Hepatology 2015;61:1643-1650)
引用
收藏
页码:1643 / 1650
页数:8
相关论文
共 50 条
  • [1] Delayed HCC MELD Exception Score Improves Disparity in Access to Liver Transplant.
    Heimbach, J.
    Hirose, R.
    Olthoff, K.
    Kim, W.
    Schladt, D.
    Xiong, H.
    Liu, J.
    Harper, A.
    Stock, P.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 89 - 89
  • [2] Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates
    Alver, Sarah K.
    Lorenz, Douglas J.
    Marvin, Michael R.
    Brock, Guy N.
    [J]. LIVER TRANSPLANTATION, 2016, 22 (10) : 1343 - 1355
  • [3] Model of end stage liver disease score and hepatocellular carcinoma
    Shabana, H.
    Askar, M.
    Elrakhawy, M.
    Haras, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 47 - 47
  • [4] MELDEQ: An Alternative Model for End-Stage Liver Disease Score for Patients With Hepatocellular Carcinoma
    Marvin, Michael R.
    Ferguson, Nicole
    Cannon, Robert M.
    Jones, Christopher M.
    Brock, Guy N.
    [J]. LIVER TRANSPLANTATION, 2015, 21 (05) : 612 - 622
  • [5] Model for end-stage liver disease score predicts survival in patients with hepatocellular carcinoma
    Contreras, C. M.
    Behrens, J.
    Cho, C. S.
    Mahvi, D. M.
    Rikkers, L. F.
    Weber, S. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 96 - 96
  • [6] Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center
    Tan, E. K.
    Goh, B. K. P.
    Lee, S. Y.
    Krishnamoorthy, T. L.
    Tan, C. K.
    Jeyaraj, P. R.
    [J]. TRANSPLANTATION PROCEEDINGS, 2018, 50 (10) : 3564 - 3570
  • [7] Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: The national experience
    Schwartz, Jason
    Thiesset, Heather
    Box, Terry
    Hutson, William
    Sorensen, John
    [J]. LIVER TRANSPLANTATION, 2012, 18 (11) : 1395 - 1396
  • [8] Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: The national experience
    Schwartz, Jason J.
    Pappas, Lisa
    Thiesset, Heather F.
    Vargas, Gabriela
    Sorensen, John B.
    Kim, Robin D.
    Hutson, William R.
    Boucher, Kenneth
    Box, Terry
    [J]. LIVER TRANSPLANTATION, 2012, 18 (04) : 423 - 433
  • [9] Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era
    Levi, David M.
    Tzakis, Andreas G.
    Martin, Paul
    Nishida, Seigo
    Island, Eddie
    Moon, Jang
    Selvaggi, Gennaro
    Tekin, Akin
    Madrazo, Beatrice L.
    Narayanan, Govindarajan
    Garcia, Monica T.
    Feun, Lynn G.
    Tryphonopoulos, Panagiotis
    Skartsis, Nikolaos
    Livingstone, Alan S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (05) : 727 - 734
  • [10] Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception
    Gerber, David A.
    Anderson, Christopher D.
    Chapman, William C.
    Jones, Christopher M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 230 (04) : 513 - 514